List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Researchers develop a knock-in mouse expressing human angiotensin-converting enzyme 2 (hACE2) to model SARS-CoV-2 infection for research and therapeutic or vaccine testing.
The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
A new suggestion has highlighted that the available pharmacologically-established existing medicines should be used to combat COVID-19.
Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount of time in order to work efficiently.
Researchers use CRISPR-Cas9 gene-editing to establish gangliosides are invoved in hepatitis A entering liver cells, revealing a potential drug target.
The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
A team used both structural and spectroscopic techniques to study the dynamics of cell surface G-protein coupled receptors (GPCRs).
The researchers revealed the mechanism by which signalling becomes dysfunctional in upper motor neuron (UMN) diseases, such as amyotrophic lateral sclerosis (ALS).
Find several chemical formulas for potential COVID-19 therapeutics and drug targets currently in development here.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
